BenzingaSeptember 2, 2026 at 8:55 AM NYLast Month
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312
Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
